THAC NEWS
THAC Secures Exclusive License for ALF5755 from University of South Florida
Innovation begins with strong ideas—and grows through the right partnerships.
The Healthy Aging Company (THAC) is proud to announce the successful execution of an exclusive license agreement with the University of South Florida (USF) for ALF5755, a promising compound advancing toward clinical development. This innovative program focuses on cognitive disorders associated with anxiety and Alzheimer’s disease, representing an important step forward in addressing significant unmet medical needs.
This milestone highlights the strength of collaboration between academia and industry and underscores the critical role of USF CONNECT in translating scientific discoveries into real-world impact. By fostering connections between research, entrepreneurship, and commercialization, USF CONNECT continues to accelerate innovation while strengthening both the university’s mission and the broader life sciences ecosystem.
At THAC, we are committed to advancing breakthrough science into meaningful solutions that improve patient outcomes and quality of life. We are proud to be part of a collaborative network that enables cutting-edge research to move closer to clinical application.
Stay tuned for future updates as we continue progressing this exciting program.
THAC have been awarded a $1.8 million grant from The Florida Cancer Innovation Fund.
We are proud to announce that The Healthy Aging Company, the University of South Florida have been awarded a $1.8 million grant from The Florida Cancer Innovation Fund.
The project will evaluate the potential of ALF5755, the leading drug candidate of the company, to mitigate the progression of Metabolically Dysfunctional Associated Steato Hepatitis (MASH) and the development of liver cancer; it will also evaluate the potential synergy of ALF5755 with GLP1 R agonists. This is a preclinical study that, based on previously demonstrated safety in humans, will lead to an IND and a first clinical study.
The grant recognizes the value of ALF5755 in restoring insulin sensitivity, mitigating inflammation, promoting tissue repair, and directly antagonizing liver cancer development.
This is a great honor, and we are thrilled to initiate the study.
THAC announces the publication of its new scientific publication in July 2022.
The scientific publication demonstrates the therapeutic rationale of its active substance for the treatment of T2DM patients, with data in humans. [♦ July 2022].
THAC has conducted a worldwide market access studies.
The « value proposition » and the « pricing potential » analysis reinforce the positioning of the future product of the Company on the market and confirms its market potential in response to an unmet medical need. [♦ June 2022].
THAC reinforces its patent portfolio with new exciting data on DPN.
THAC reinforces a submitted patent related to its product in diabetic peripheral neuropathy (DPN) with new preclinical existing results obtained by the team. Diabetic peripheal neuropathy is one of the most severe and costly complications of T2DM, leading to amputations [♦ May 2022].
THAC submitted a new patent which will reinforce the protection of its first product.
The new patent was submitted on the basis of new exciting preclinical results, in relation with its product under development. This patent will allow to reinforce the protection of the product within time. [♦ April 2022].
THAC contributes to elaborate the 2030 Healthcare Innovation Plan
Emmanuel Macron, French President, announced an ambitious plan prepared by the 5 Qualified Personalities including Lyse Santoro, CEO of THAC: 7 billion euros to boost healthcare Innovation, in particular in companies such as THAC [♦ June 2021].
New patent for early T2DM treatment and gut microbiota composition
This new patent strengthens the protection and the potential of the « First in Class » drug candidate pf the Company. it allows to develop a further oral formulation for a second product, which acts directly on the gut microbiota of T2DM patients [♦ October 2021].
Launch of the CSIS 2021
Lyse Santoro, CEO of THAC, is nominated by the French Government as Qualified Personality to conduct the Strategic Council for the Healthcare Industry in order to propose a ambitious 10-years plan for innovation in healthcare. [♦ February 2021].
[PARTNERS] – THAC launches a crowdfunding campaign
THAC launches a crowdfunding campaign with the plateform Happy Capital in order to allow healthcare patients and actors to contribute to the THAC story for the benefit of T2DM patients [♦ July 2020]
